Aditya Bardia, Virginia G. Kaklamani, Joyce O'Shaughnessy, Peter Schmid, J. Thaddeus Beck, Michelino De Laurentiis, Giuseppe Curigliano, Hope S. Rugo, Carlos Hernando Barcenas, William John Gradishar, Michail Ignatiadis, David A. Cameron, Giulia Tonini, Simona Scartoni, Jennifer A. Crozier, Tomer Wasserman, Sara M. Tolaney. "ELEGANT: Elacestrant versus standard endocrine therapy (ET) in women and men with node-positive, estrogen receptor–positive (ER+), HER2-negative (HER2−), early breast cancer (eBC) with high risk of recurrence in a global, multicenter, randomized, open-label phase 3 study.." Journal of Clinical Oncology, 2026. doi:10.1200/jco.2026.44.16_suppl.tps1153